Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants

被引:30
作者
Epstein, JB
Ransier, A
Lunn, R
Chin, E
Jacobson, JJ
Le, N
Reece, D
机构
[1] VANCOUVER HOSP & HLTH SCI CTR, DEPT DENT, VANCOUVER, BC, CANADA
[2] UNIV BRITISH COLUMBIA, VANCOUVER, BC V5Z 1M9, CANADA
[3] UNIV WASHINGTON, SEATTLE, WA 98195 USA
[4] VANCOUVER COMMUNITY COLL, VANCOUVER, BC, CANADA
[5] UNIV MICHIGAN, SCH DENT, ANN ARBOR, MI 48109 USA
[6] BRITISH COLUMBIA CANC AGCY, DEPT EPIDEMIOL BIOMETRY & OCCUPAT ONCOL, VANCOUVER, BC V5Z 4E6, CANADA
[7] VANCOUVER HOSP & HLTH SCI CTR, DEPT HEMATOL, VANCOUVER, BC, CANADA
[8] BRITISH COLUMBIA CANC AGCY, HLTH SCI CTR, VANCOUVER, BC V5Z 4E6, CANADA
来源
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY | 1996年 / 81卷 / 03期
关键词
D O I
10.1016/S1079-2104(96)80328-3
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objectives. The increased risk for systemic fungal infection and the potential fatal consequences of disseminated candidiasis in bone marrow transplant patients has prompted study of prophylaxis and early treatment of candida colonization and infection. Study design. Patients with leukemia who received fluconazole prophylaxis were compared with a concurrent group of patients not given prophylaxis for fungal organisms. Results. A trend to reduction of oropharyngeal colonization by Candida albicans was seen (p = 0.07) although no significant differences in systemic candidiasis were seen. In patients with documented systemic candidiasis, oral colonization was present and systemic infection was identified after the development of ulcerative oral mucositis. Conclusions. Our results support the potential of fluconazole to reduce oropharyngeal colonization caused by Candida albicans, however, we did not show prophylaxis of oral candidiasis or systemic candidiasis. These findings and reports of fluconazole-resistant candidal species and a rising number of cases of infection as a result of Candida krusei indicate the need for further studies of prophylaxis of candidal infection in patients who are anticipated to develop profound neutropenia.
引用
收藏
页码:291 / 296
页数:6
相关论文
共 70 条
[1]  
Alsip S.A., 1986, FUNGAL DISEASES LUNG, P335
[2]   FLUCONAZOLE THERAPY FOR CHRONIC DISSEMINATED CANDIDIASIS IN PATIENTS WITH LEUKEMIA AND PRIOR AMPHOTERICIN-B THERAPY [J].
ANAISSIE, E ;
BODEY, GP ;
KANTARJIAN, H ;
DAVID, C ;
BARNETT, K ;
BOW, E ;
DEFELICE, R ;
DOWNS, N ;
FILE, T ;
KARAM, G ;
POTTS, D ;
SHELTON, M ;
SUGAR, A .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 (02) :142-150
[3]   EVALUATION OF NYSTATIN IN PREVENTION AND ELIMINATION OF OROPHARYNGEAL CANDIDA IN IMMUNOSUPPRESSED PATIENTS [J].
BARRETT, AP .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 1984, 58 (02) :148-151
[4]   A LONG-TERM PROSPECTIVE CLINICAL-STUDY OF ORAL COMPLICATIONS DURING CONVENTIONAL CHEMOTHERAPY FOR ACUTE-LEUKEMIA [J].
BARRETT, AP .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 1987, 63 (03) :313-316
[5]  
BENDER JF, 1979, EUR J CANCER, V15, P35
[6]  
BERKOWITZ RJ, 1983, AM J PEDIAT HEMATOL, V5, P53
[7]  
BODEY GP, 1984, AM J MED, V77, P13
[8]   TREATMENT OF ORAL CANDIDIASIS IN DEBILITATED PATIENTS WITH MICONAZOLE - NEW POTENT ANTIFUNGAL DRUG [J].
BRINCKER, H .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1976, 8 (02) :117-120
[9]  
CAP J, 1993, CHEMOTHERAPY, V39, P438, DOI 10.1159/000238990
[10]  
CARPENTIERI U, 1978, J PEDIATR-US, V92, P593, DOI 10.1016/S0022-3476(78)80298-4